ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Acquired by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. boosted its stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 64.6% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 44,829 shares of the biotechnology company’s stock after purchasing an additional 17,595 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in ADMA Biologics were worth $896,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in ADMA. USA Financial Formulas boosted its position in ADMA Biologics by 8.6% during the 3rd quarter. USA Financial Formulas now owns 6,817 shares of the biotechnology company’s stock worth $136,000 after acquiring an additional 539 shares during the period. Vontobel Holding Ltd. boosted its position in ADMA Biologics by 7.0% during the 3rd quarter. Vontobel Holding Ltd. now owns 13,643 shares of the biotechnology company’s stock worth $273,000 after acquiring an additional 888 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in ADMA Biologics by 21.8% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,430 shares of the biotechnology company’s stock worth $163,000 after acquiring an additional 1,509 shares during the period. Quest Partners LLC acquired a new position in ADMA Biologics during the 2nd quarter worth $29,000. Finally, Arizona State Retirement System boosted its position in ADMA Biologics by 4.5% during the 2nd quarter. Arizona State Retirement System now owns 61,641 shares of the biotechnology company’s stock worth $689,000 after acquiring an additional 2,645 shares during the period. Institutional investors and hedge funds own 75.68% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. HC Wainwright reiterated a “buy” rating and set a $18.00 price target on shares of ADMA Biologics in a research report on Monday, October 14th. Cantor Fitzgerald reiterated an “overweight” rating and set a $20.00 price target on shares of ADMA Biologics in a research report on Friday, September 20th. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, ADMA Biologics presently has a consensus rating of “Buy” and a consensus target price of $15.50.

Insider Transactions at ADMA Biologics

In other news, CEO Adam S. Grossman sold 236,889 shares of the business’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the sale, the chief executive officer now directly owns 2,059,726 shares of the company’s stock, valued at $36,436,552.94. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, Director Young Kwon sold 60,000 shares of the business’s stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $18.26, for a total transaction of $1,095,600.00. Following the sale, the director now directly owns 241,441 shares of the company’s stock, valued at $4,408,712.66. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Adam S. Grossman sold 236,889 shares of the business’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $17.69, for a total value of $4,190,566.41. Following the sale, the chief executive officer now directly owns 2,059,726 shares in the company, valued at $36,436,552.94. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 466,900 shares of company stock valued at $8,224,121 over the last three months. Company insiders own 3.70% of the company’s stock.

ADMA Biologics Stock Up 1.7 %

ADMA opened at $16.71 on Wednesday. ADMA Biologics, Inc. has a one year low of $3.23 and a one year high of $21.13. The company has a debt-to-equity ratio of 0.74, a quick ratio of 2.80 and a current ratio of 6.87. The stock’s fifty day moving average is $17.90 and its 200-day moving average is $13.15. The company has a market capitalization of $3.87 billion, a PE ratio of -835.50 and a beta of 0.62.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Thursday, August 8th. The biotechnology company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.08 by $0.05. ADMA Biologics had a return on equity of 38.79% and a net margin of 10.53%. The company had revenue of $107.20 million for the quarter, compared to the consensus estimate of $86.44 million. During the same quarter in the previous year, the business earned ($0.02) EPS. The company’s quarterly revenue was up 78.4% compared to the same quarter last year. On average, equities analysts predict that ADMA Biologics, Inc. will post 0.49 EPS for the current fiscal year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.